Posted by Michael Wonder on 13 Feb 2023
Mitsubishi Tanabe Pharma Canada announces Radicava (edaravone) oral suspension is now available in Canada for the treatment of patients with ALS
10 February 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension, the oral formulation of Radicava IV (edaravone), is now commercially available in Canada for the treatment of patients with amyotrophic lateral sclerosis.
Radicava oral suspension is the first and only oral treatment option for amyotrophic lateral sclerosis, which has been granted a Notice of Compliance by Health Canada following priority review.
